Skip to main content
Premium Trial:

Request an Annual Quote

Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics

NEW YORK ─ RNA-based diagnostics firm GeneCentric Therapeutics announced Tuesday a new strategic collaboration with Laboratory Corporation of America to develop and commercialize RNA-based signatures for diagnosing cancer.

Durham, North Carolina-based GeneCentric will develop the signatures in collaboration with Labcorp Drug Development, with tests produced through the project deployed to major academic and community cancer centers through Labcorp Diagnostics.

The companies will use retrospective analyses of Burlington, North Carolina-based Labcorp's de-identified clinical and genomic data and GeneCentric's pharmaceutical and biotechnology partnerships.

The arrangement builds on a previous relationship between the two firms. GeneCentric is eligible to earn milestone payments through the deal, and Labcorp has made an upfront investment in the company.

"Labcorp has been a great partner as GeneCentric pioneered RNA-based gene signature technology and diagnostics to where they are today," Michael Milburn, GeneCentric president and CEO, said in a statement. "They have an established track record of innovation in the precision medicine space with their extensive menu of companion and complementary diagnostic tests, as well as a shared vision for the promise of RNA signatures as the next generation of cancer diagnostics. This expanded collaboration will be instrumental in helping us commercialize our novel, RNA-based diagnostics."

"Our latest strategic collaboration with GeneCentric will draw upon their industry-leading RNA-based signatures and help facilitate the creation of better tools for oncology diagnostics, drug development and patient care," said Steven Anderson, senior vice president and chief scientific officer at Labcorp Drug Development. "The new diagnostics developed through this arrangement will further our goal of enabling physicians to improve outcomes by tailoring treatment options based on precision medicine."

The Scan

Billion-Dollar Diversity Initiative

The Howard Hughes Medical Institute is now accepting applications for its new $1.5 billion initiative to boost the diversity of the scientific workforce.

Biotech Co-Founder Arrested

A co-founder of a Los Angeles-based biotech company has been arrested in connection with a murder-for-hire scheme, according to Endpoint News.

Return of the Tasmanian Tiger

The Washington Post reports that a team in Australia is working to bring the thylacine back from extinction.

Nature Papers on Genome of Individual From Pompeii, CircRNA Study Best Practices, More

In Nature this week: first sequenced genome of a person from Pompeii, best practice guidelines for circRNA studies, and more.